⌘K

16:23:42·436d

SECFilingvia Quantisnow

Cidara Therapeutics Inc. filed SEC Form 8-K: Leadership Update

ByQuantisnow·Wall Street's wire, on your screen.

CDTX· Cidara Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

CDTX
Cidara Therapeutics Inc.
Health Care

Recent analyst ratings

Nov 17UpdateMorgan Stanley-
Nov 17UpdateAnalyst-
Nov 17UpdateRBC Capital Mkts-
Oct 16UpdateMorgan Stanley$190.00
Oct 10UpdateAnalyst$200.00
Jun 18UpdateH.C. Wainwright$41.00

Related

SEC100d
SEC Form 15-12G filed by Cidara Therapeutics Inc.
SEC109d
SEC Form EFFECT filed by Cidara Therapeutics Inc.
SEC109d
SEC Form EFFECT filed by Cidara Therapeutics Inc.
SEC109d
SEC Form EFFECT filed by Cidara Therapeutics Inc.
SEC109d
SEC Form EFFECT filed by Cidara Therapeutics Inc.
SEC109d
SEC Form EFFECT filed by Cidara Therapeutics Inc.
SEC109d
SEC Form EFFECT filed by Cidara Therapeutics Inc.
INSIDER111d
Director Ra Capital Management, L.P. exercised 1,286,786 shares at a strike of $0.00 and returned $1,030,486,444 worth of shares to the company (4,652,309 units at $221.50) (SEC Form 4)

Cidara Therapeutics Inc. filed SEC Form 8-K: Leadership Update | Quantisnow